Tudorza Pressair Approved for COPD

TUESDAY, July 24 (HealthDay News) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive pulmonary disease (COPD) in people 18 and older.

COPD, most often caused by smoking, encompasses chronic bronchitis and emphysema. Symptoms usually include chronic cough, excessive phlegm and chest tightness, the FDA said in a news release.

The Tudorza Pressair inhaler, to be used twice daily, relaxes muscles around the lung's large airways, improving breathing. It is not meant to be used as a rescue inhaler during sudden asthma attacks, the agency said.

Common side effects observed during clinical testing included headache, nasal inflammation and cough.

The inhaler is distributed by St. Louis-based Forest Pharmaceuticals, a subsidiary of Forest Laboratories.

More information

Medline Plus has details about COPD.

Related Articles

Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.

Health News is provided as a service to Sharp Web site users by HealthDay. Sharp HealthCare nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please read the Terms of Use for more information.